Biotech Values

[DewDiligence]

Re: Sell-side models for GILD

I commented on Stifel’s model in #msg-101479601, and jq1234 commented (with my concordance) on CS’ model in #msg-101066487.

I haven’t previously commented on Nomura’s model, but I now see that they (mistakenly) think treatment-experienced non-cirrhotic patients will get only 8 weeks of Sovaldi + Ledipasvir—i.e. they appear to be guilty of the same bias as Stifel.

Feedback welcome.

p.s. It might be helpful to readers (at the cost of some extra work by you) to highlight the changes in each iteration in bold-faced or colored text.